Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EVP AND GROUP PRESIDENT | February 27, 2026 | March 04, 2026 |
| NEVRO CORPNVRO · Entity 12422 | Director | May 21, 2018 | May 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 90,407 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 8,577 · Balance 90,407 |
NEVRO CORP
Report date May 21, 2018 · Filed May 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,303 |
Reported balance
After 2018-05-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-21 · Grant · Acquired 3,785 · Balance 5,303 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2: Includes 3,785 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer.
F2: Includes 3,785 RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intersect ENT, Inc.
Report date July 24, 2019 · Filed July 26, 2019
Section 16 reporting ended · disclosed 2019-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-24 · Disposition to issuer · Disposed 44,625 · Balance 0 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2019-12-06 | Direct | 44,625 |
Reported balance
After 2019-07-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-24 · Grant · Acquired 44,625 · Balance 44,625 F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.06 · Expires 2019-12-06 | Direct | 150,000 |
Reported balance
After 2019-07-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-24 · Grant · Acquired 150,000 · Balance 150,000 F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-07-24 · Disposition to issuer · Disposed 196,875 · Balance 0 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2019-12-06 | Direct | 196,875 |
Reported balance
After 2019-07-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-07-24 · Grant · Acquired 196,875 · Balance 196,875 F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-07-24 · Disposition to issuer · Disposed 45,500 · Balance 0 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2019-12-06 | Direct | 45,500 |
Reported balance
After 2019-07-24 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-07-24 · Grant · Acquired 45,500 · Balance 45,500 F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-07-24 · Disposition to issuer · Disposed 48,333 · Balance 0 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2019-12-06 | Direct | 48,333 |
Reported balance
After 2019-07-24 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-07-24 · Grant · Acquired 48,333 · Balance 48,333 F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-10-22 | Direct | 0 |
Reported balance
After 2019-07-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-07-24 · Disposition to issuer · Disposed 19,688 · Balance 0 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2019-12-06 | Direct | 19,688 |
Reported balance
After 2019-07-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-07-24 · Grant · Acquired 19,688 · Balance 19,688 F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 353,183 |
Reported balance
Holding disclosure · report date 2019-07-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 353,183 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 26,182 |
Reported balance
Holding disclosure · report date 2019-07-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 26,182 F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares in the name of Lisa Damkroger Earnhardt C/F Jack L. Earnhardt UTMA/CA Until Age 25 for the benefit of Reporting Person's son. Reporting Person disclaims beneficial ownership of these shares.
F2: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 17, 2018 and 1/8th of the shares subject to the option vested on July 1, 2018 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F3: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 16, 2019 and 1/8th of the shares subject to the option vested on July 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F4: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 21, 2015 and 1/8th of the shares subject to the option vested on July 1, 2015 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
F5: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 15, 2016 and vest in equal monthly installments over four years. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F6: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 18, 2017 and 1/8th of the shares subject to the option vested on July 1, 2017 and 1/48th of the shares subject to the option vest monthly thereafter over 42 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019. All other shares subject to the 'old' option have been cancelled.
F7: The two reported transactions involved an amendment of an outstanding option extending the post-termination exercise period from 90 days to 135 days, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 23, 2013, 1/48th of the shares subject to the option vested on December 30, 2013 and 1/48th of the shares subject to the option vested monthly thereafter over 47 months. The number of shares reflected herein represent the number of outstanding shares that have vested as of July 24, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2018 Filed Jan 19, 2018 17:17 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-000368 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,849 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in equal annual installments over three years commencing on January 1, 2018. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 20:09 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Tax withholdingCommon Stock | 6,834 | $33.93 | $231,896.76 |
DisclosureSEC source: 0001562180-18-000161 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,349 F1 · shares: Shares tendered in payment of the tax withholding obligation. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.25, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 19:17 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-003924 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,016 Underlying: Common Stock · 2,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 19:17 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 10,685 | $31.87 | $340,511.72 |
DisclosureSEC source: 0001562180-17-003924 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,183 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.75 to $32.15, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 19:17 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 2,000 | $1.20 | $2,400.00 |
DisclosureSEC source: 0001562180-17-003924 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 16:46 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-003629 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 16:46 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $27.88 | $557,620.00 |
DisclosureSEC source: 0001562180-17-003629 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.20, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 16:46 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-003629 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 17:01 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-003271 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,016 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 17:01 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $28.37 | $567,336.00 |
DisclosureSEC source: 0001562180-17-003271 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.50, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| October 16, 2017 Filed Oct 17, 2017 17:01 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-003271 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:35 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-002986 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,016 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:35 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $30.19 | $603,870.00 |
DisclosureSEC source: 0001562180-17-002986 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.50, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:35 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-002986 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:33 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-002732 · primarydocument.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,016 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:33 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $30.79 | $615,810.00 |
DisclosureSEC source: 0001562180-17-002732 · primarydocument.xml · nonDerivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,868 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.60 to $31.00, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:33 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-002732 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 535,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 17, 2017 17:33 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GiftCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002732 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,868 F1 · kind: The transaction reported involved a gift by the reporting person of 35,000 shares of common stock to a charitable donor advised fund. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 17:50 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-002491 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,016 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 17:50 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $29.03 | $580,642.00 |
DisclosureSEC source: 0001562180-17-002491 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.90 to $29.25, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 17:50 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-002491 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:42 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 2,625 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-002298 · primarydocument.xml · derivative · entry 6 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,016 Underlying: Common Stock · 2,625 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest commencing November 30, 2013 in monthly equal installments over four years. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:42 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 7,375 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-002298 · primarydocument.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,375 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:42 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $26.10 | $521,978.00 |
DisclosureSEC source: 0001562180-17-002298 · primarydocument.xml · nonDerivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.40, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:42 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 7,375 | $1.20 | $8,850.00 |
DisclosureSEC source: 0001562180-17-002298 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:42 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 2,625 | $1.20 | $3,150.00 |
DisclosureSEC source: 0001562180-17-002298 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 30, 2017 18:50 UTC | NEVRO CORP NVRO · Entity 12422 | GrantStock Option (Right to Buy) · Derivative | 3,545 | $0.00 Strike: $74.07 | $0.00 |
DisclosureSEC source: 0001140361-17-022918 · doc1.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,545 Underlying: Common Stock · 3,545 shares Expires 2027-05-24 F3 · derivative.exercise_date: 1/12th of the shares subject to the option vest on each monthly anniversary measured from May 25, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the first anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the issuer. Read SEC document |
| May 25, 2017 Filed May 30, 2017 18:50 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022918 · doc1.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of May 25, 2017, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 1,518 RSUs. Read SEC document |
| May 15, 2017 Filed May 16, 2017 17:16 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-001967 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,375 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| May 15, 2017 Filed May 16, 2017 17:16 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $22.98 | $459,520.00 |
DisclosureSEC source: 0001562180-17-001967 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.80 to $23.15, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| May 15, 2017 Filed May 16, 2017 17:16 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-001967 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 17:59 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-001520 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,375 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 17:59 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $16.06 | $321,244.00 |
DisclosureSEC source: 0001562180-17-001520 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.20, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| April 17, 2017 Filed Apr 18, 2017 17:59 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-001520 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 19:14 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-001284 · primarydocument.xml · derivative · entry 5 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375 Underlying: Common Stock · 10,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 19:14 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 10,000 | $15.02 | $150,188.00 |
DisclosureSEC source: 0001562180-17-001284 · primarydocument.xml · nonDerivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.90 to $15.10, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 19:14 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 10,000 | $15.03 | $150,265.00 |
DisclosureSEC source: 0001562180-17-001284 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.95 to $15.10, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 19:14 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-17-001284 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 18:30 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-17-000808 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,375 Underlying: Common Stock · 20,000 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 18:30 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 20,000 | $13.01 | $260,170.00 |
DisclosureSEC source: 0001562180-17-000808 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 18:30 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 20,000 | $1.20 | $24,000.00 |
DisclosureSEC source: 0001562180-17-000808 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 252,000 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001562180-17-000298 · primarydocument.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Common Stock · 252,000 shares Expires 2027-01-17 F3 · derivative.exercise_date: 1/8th of the shares subject to the option vest on July 1, 2017 and 1/48th of the total shares subject to the option vest monthly thereafter over 42 months. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000298 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,868 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in equal annual installments over three years commencing on January 1, 2017. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:04 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionStock Options (Right to buy) · Derivative | 400 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-16-003251 · primarydocument.xml · derivative · entry 4 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,975 Underlying: Common Stock · 400 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing April 23, 2013 in monthly equal installments over four years. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:04 UTC | Intersect ENT, Inc. XENT · Entity 127294 | SaleCommon Stock | 400 | $18.00 | $7,200.00 |
DisclosureSEC source: 0001562180-16-003251 · primarydocument.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,868 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2015. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 20:04 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Exercise / conversionCommon Stock | 400 | $1.20 | $480.00 |
DisclosureSEC source: 0001562180-16-003251 · primarydocument.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.